The miR-29b Byproduct MIRTX Shows Superior Anti-tumor Activity, Compared to miR-29b-3p, in Pancreatic Cancer Cells

Authors

Daisuke Okuzaki (ORCID: https://orcid.org/0000-0002-4552-783X)
Akira Inoue
Yingjue Zhang
Masaki Mori (ORCID: https://orcid.org/0000-0001-8093-8848)
Yuki Sekido (ORCID: https://orcid.org/0000-0003-4281-0047)
Satoshi Shibata (ORCID: https://orcid.org/0000-0002-9917-7847)
YOSHIHIRO MORIMOTO
YUMA IRIE
MANAMI TSUJIMOTO
RUIJIA YANG
HIROYUKI YAMAMOTO
NANAMI NAGATA
TSUYOSHI HATA
HIROFUMI YAMAMOTO

Institutions

Osaka Gakuin University (JP)
Tokai University (JP)
Osaka Prefectural Medical Center (JP)
Osaka City General Hospital (JP)
Ikeda Municipal Hospital (JP)
The University of Osaka (JP)

Publication Details

Journal: Anticancer Research
Published: 2026-01-30
DOI: https://doi.org/10.21873/anticanres.17974
Primary Topic: MicroRNA in disease regulation
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Japan Society for the Promotion of Science

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

The miR-29b Byproduct MIRTX Shows Superior Anti-tumor Activity, Compared to miR-29b-3p, in Pancreatic Cancer Cells

Daisuke Okuzaki, Akira Inoue, Yingjue Zhang, Masaki Mori et al.

Jan 30, 2026

Anticancer Research

MicroRNA in disease regulation

article

The miR-29b Byproduct MIRTX Shows Superior Anti-tumor Activity, Compared to miR-29b-3p, in Pancreatic Cancer Cells

Daisuke Okuzaki, Akira Inoue, Yingjue Zhang, Masaki Mori, Yuki Sekido, Satoshi Shibata, YOSHIHIRO MORIMOTO, YUMA IRIE, MANAMI TSUJIMOTO, RUIJIA YANG, HIROYUKI YAMAMOTO, NANAMI NAGATA, TSUYOSHI HATA, HIROFUMI YAMAMOTO

January 30, 2026article en

Abstract

No abstract available for this paper.

Anticancer ResearchVol. 46(2)

Osaka Gakuin University (JP), Tokai University (JP), Osaka Prefectural Medical Center (JP), Osaka City General Hospital (JP), Ikeda Municipal Hospital (JP), The University of Osaka (JP)

Japan Society for the Promotion of Science

Good health and well-being

Openalex Percentile: Top 73%

MicroRNA in disease regulation

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

The miR-29b Byproduct MIRTX Shows Superior Anti-tumor Activity, Compared to miR-29b-3p, in Pancreatic Cancer Cells — Daisuke Okuzaki, Akira Inoue, et al. · Anticancer Research (2026) | TGRS Research Map | TGRS